Back
42
Day Range
$25.45
$26.55
52-Week Range
$14.22
$30.42
Volume
1,879,454
50D / 200D Avg
$26.27
/
$21.87
Prev Close
$24.89
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 90.3 | 0.4 |
| P/B | 1.4 | 2.9 |
| ROE % | 1.6 | 3.8 |
| Net Margin % | 1.7 | 3.9 |
| Rev Growth 5Y % | 2.0 | 10.0 |
| D/E | 0.6 | 0.2 |
Analyst Price Target
Hold
$27.22
+5.4%
Low: $19.00
High: $35.00
Forward P/E
18.3
Forward EPS
$1.41
EPS Growth (est.)
+0.0%
Est. Revenue
2.8 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2029 |
$1.89
$1.87 – $1.92
|
3.1 B | 1 |
| FY2028 |
$1.73
$1.16 – $2.23
|
3 B | 3 |
| FY2027 |
$1.56
$1.52 – $1.63
|
2.9 B | 10 |
Key Takeaways
Revenue grew 2.04% annually over 5 years — modest growth
ROE of 1.56% is below average
Generating 230.40M in free cash flow
P/E of 90.33 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 6.28%
Cash machine — converts 490.21% of earnings into free cash flow
Growth
Revenue Growth (5Y)
2.04%
Revenue (1Y)8.32%
Earnings (1Y)N/A
FCF Growth (3Y)2.92%
Quality
Return on Equity
1.56%
ROIC3.52%
Net Margin1.73%
Op. Margin8.30%
Safety
Debt / Equity
0.55
Current Ratio2.38
Interest Coverage6.17
Valuation
P/E Ratio
90.33
P/B Ratio1.37
EV/EBITDA21.01
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8.32% | Revenue Growth (3Y) | 2.94% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 2.04% | Earnings Growth (5Y) | -39.05% |
| Profitability | |||
| Revenue (TTM) | 2.72B | Net Income (TTM) | 47.00M |
| ROE | 1.56% | ROA | 0.83% |
| Gross Margin | 55.02% | Operating Margin | 8.30% |
| Net Margin | 1.73% | Free Cash Flow (TTM) | 230.40M |
| ROIC | 3.52% | FCF Growth (3Y) | 2.92% |
| Safety | |||
| Debt / Equity | 0.55 | Current Ratio | 2.38 |
| Interest Coverage | 6.17 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 90.33 | P/B Ratio | 1.37 |
| P/S Ratio | 1.56 | PEG Ratio | -0.74 |
| EV/EBITDA | 21.01 | Dividend Yield | 0.00% |
| Market Cap | 4.25B | Enterprise Value | 4.74B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.72B | 2.51B | 2.57B | 2.57B | 2.51B |
| Net Income | 47.00M | -1.12B | -100.20M | 243.10M | 340.50M |
| EPS (Diluted) | 0.28 | -6.50 | -0.60 | 1.34 | 1.48 |
| Gross Profit | 1.50B | 1.39B | 1.45B | 1.49B | 1.46B |
| Operating Income | 225.70M | -1.04B | 31.50M | 319.20M | 306.20M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 5.68B | 5.35B | 6.61B | 6.59B | 6.57B |
| Total Liabilities | 2.57B | 2.42B | 2.43B | 2.38B | 2.52B |
| Shareholders' Equity | 3.11B | 2.93B | 4.17B | 4.21B | 4.06B |
| Total Debt | 1.71B | 1.55B | 1.65B | 1.53B | 1.48B |
| Cash & Equivalents | 1.21B | 1.07B | 940.00M | 606.90M | 1.07B |
| Current Assets | 2.03B | 1.79B | 1.74B | 1.42B | 1.84B |
| Current Liabilities | 852.60M | 878.70M | 780.80M | 1.24B | 1.21B |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#581 of 1024
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026